{"id":6275,"date":"2025-02-13T16:47:10","date_gmt":"2025-02-13T16:47:10","guid":{"rendered":"https:\/\/healthnews.zone\/?p=6275"},"modified":"2025-02-13T16:47:10","modified_gmt":"2025-02-13T16:47:10","slug":"mount-sinai-researchers-close-in-on-a-cure-for-diabetes","status":"publish","type":"post","link":"https:\/\/healthnews.zone\/?p=6275","title":{"rendered":"Mount Sinai Researchers Close in on a Cure for Diabetes"},"content":{"rendered":"\n

For hundreds of millions of people worldwide who suffer from diabetes, a cure has long remained out of reach. However, new research from the Icahn School of Medicine at Mount Sinai suggests that this reality may soon change. Scientists at Mount Sinai have uncovered a groundbreaking approach to regenerating insulin-producing beta cells, potentially offering a permanent treatment for the disease.<\/p>\n\n\n\n

Diabetes affects approximately 537 million people worldwide and occurs when the pancreas fails to produce enough insulin to regulate blood sugar levels. Without insulin, blood sugar levels become dangerously high, leading to serious health complications such as heart disease, nerve damage, and kidney failure. Current treatments help manage diabetes symptoms but do not address the root problem\u2014the loss of beta cells. Researchers at Mount Sinai have been working for over 15 years to solve this issue by developing a drug that could trigger beta cell regeneration.<\/p>\n\n\n\n

The Discovery of Harmine and Its Role in Beta Cell Regeneration<\/h3>\n\n\n\n

Mount Sinai\u2019s groundbreaking research began in 2015 when scientists discovered that a drug called harmine could stimulate the regeneration of beta cells. Harmine belongs to a class of drugs known as DYRK1A inhibitors, which regulate cell growth. Researchers found that harmine could make beta cells replicate, but at the time, the effect was not strong enough to be a practical treatment. Over the next several years, researchers worked to improve harmine\u2019s regenerative potential.<\/p>\n\n\n\n

By 2019 and 2020, Mount Sinai scientists discovered that harmine worked even better when combined with other drugs, such as GLP-1 receptor agonists (GLP-1RAs), including semaglutide (Ozempic) and exenatide (Byetta). These combinations significantly enhanced beta cell growth. Then, in July 2024, the research team made their most exciting breakthrough yet. They found that harmine alone could increase beta cell mass by 300%, but when paired with a GLP-1RA, the increase jumped to an astonishing 700%.<\/p>\n\n\n\n

The Unexpected Role of Alpha Cells<\/h3>\n\n\n\n

One of the most remarkable findings of the study is the potential role of alpha cells in beta cell regeneration. Alpha cells, another type of pancreatic cell, are responsible for producing glucagon, a hormone that raises blood sugar levels. Researchers previously believed that beta cells were the only source of insulin production, but the new study suggests that alpha cells could be reprogrammed to function as beta cells.<\/p>\n\n\n\n

\u201cThis is an exciting finding that shows harmine-family drugs may be able to induce lineage conversion in human pancreatic islets,\u201d said Dr. Esra Karakose, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and the corresponding author of the study. \u201cIt may mean that people with all forms of diabetes have a large potential \u2018reservoir\u2019 for future beta cells, just waiting to be activated by drugs like harmine.\u201d<\/p>\n\n\n\n

If alpha cells can be converted into beta cells, it could provide an almost limitless source of insulin-producing cells for diabetics. This discovery is especially significant for those with Type 1 diabetes, who have lost most or all of their beta cells due to autoimmune attacks.<\/p>\n\n\n\n

The Next Steps: Moving Toward Human Trials<\/h3>\n\n\n\n

With such promising results, the next step for the Mount Sinai team is to move their research into human trials. The ultimate goal is to develop an oral medication that could stimulate the regeneration of beta cells in diabetic patients.<\/p>\n\n\n\n

\u201cIt has been remarkable and rewarding to watch this multi-group story unfold over the past 15 years,\u201d said Dr. Andrew F. Stewart, Director of the Mount Sinai Diabetes, Obesity, and Metabolism Institute. \u201cA simple pill, perhaps together with a GLP-1RA like semaglutide, is affordable and scalable to the millions of people with diabetes.\u201d<\/p>\n\n\n\n

Dr. Stewart and his colleague Dr. Peng Wang, Professor of Medicine at Mount Sinai, were among the original researchers who screened thousands of drugs to identify harmine\u2019s potential in 2015. Their work, published in Nature Medicine<\/em>, laid the foundation for the latest discoveries.<\/p>\n\n\n\n

The research team includes experts across multiple fields, such as genetics, bioinformatics, and pharmacology. Key contributors include Dr. Dan Hasson, Director of the Bioinformatics and Next-Generation Sequencing Core, and Dr. Robert Sebra, Director of the Center for Advanced Genomic Technology. Their combined expertise has been crucial in uncovering harmine\u2019s full potential.<\/p>\n\n\n\n

Potential Impact on Global Health<\/h3>\n\n\n\n

If successful, this discovery could transform diabetes treatment and significantly reduce healthcare costs worldwide. Diabetes management is expensive, requiring constant monitoring, medication, and insulin injections. A regenerative drug that restores the body\u2019s natural ability to produce insulin could eliminate these burdens.<\/p>\n\n\n\n